Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio, Inc. (TIL)
NASDAQ:AMEX Investor Relations:
nasdaq.com/symbol/til
Company Research
Source: GlobeNewswire
In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. “We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M,” said Bronson Crouch, CEO of Instil. “By executing a 15-year lease of our Tarzana cell therapy manufacturing facility, we have strengthened our financial foundation to support Instil’s near-term clinical development of these assets.” Recent Highlights: In-licensed SYN-2510 and SYN-27M: In August 2024, SynBioTx, I
Show less
Read more
Impact Snapshot
Event Time:
TIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TIL alerts
High impacting Instil Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TIL
News
- Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast CancerGlobeNewswire
- Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? [Yahoo! Finance]Yahoo! Finance
- Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]Seeking Alpha
- Futures Gain As Expectations For A 50bps Rate Cut Spike [zero hedge]zero hedge
- Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week [Yahoo! Finance]Yahoo! Finance
TIL
Earnings
- 8/13/24 - Beat
TIL
Sec Filings
- 10/25/24 - Form SC
- 10/22/24 - Form SC
- 9/27/24 - Form SC
- TIL's page on the SEC website